OMBITASVIR; PARITAPREVIR; RITONAVIR
| Brand name | TECHNIVIE |
|---|---|
| Active ingredient | OMBITASVIR; PARITAPREVIR; RITONAVIR |
| Strength | 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2015 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 8691938 | April 2032 | substance, product |
| 8420596*PED | October 2031 | — |
| 8686026 | June 2031 | product |
| 8420596 | April 2031 | substance, product |
| 9044480 | April 2031 | use U-1638 |
| 9006387 | June 2030 | use U-1687 |
| 8642538 | September 2029 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.